Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.61 |
| ▸ | MAOA | P21397 | 1/20 | 0.61 |
| ▸ | MAOB | P27338 | 1/20 | 0.61 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.61 |
| ▸ | FER | P16591 | 1/20 | 0.61 |
| ▸ | LTK | P29376 | 1/20 | 0.61 |
| ▸ | CDK8 | P49336 | 1/20 | 0.61 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.61 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | PLK4 | O00444 | 3/20 | 0.51 |
| ▸ | PLK1 | P53350 | 3/20 | 0.51 |
| ▸ | RET | P07949 | 1/20 | 0.51 |
| ▸ | FLT3 | P36888 | 1/20 | 0.51 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2420711 | 0.80 | LRRK2 (0.90) | LRRK2MAOAMAOBPDGFRAFER | |
| SCHEMBL366728 | 0.80 | — | — | |
| SCHEMBL28886187 | 0.77 | LRRK2 (0.75) | LRRK2MAOAMAOBPDGFRAFER | |
| Isoindigo SCHEMBL9899740 | 0.76 | LRRK2 (0.67) | LRRK2MAOAMAOBPDGFRAFER | |
| Isoindigo SCHEMBL12386233 | 0.76 | LRRK2 (0.67) | LRRK2MAOAMAOBPDGFRAFER | |
| Isatin SCHEMBL973760 | 0.76 | MAOA (1.00) | LRRK2MAOAMAOBPDGFRAFER | |
| Isoindigo SCHEMBL9899736 | 0.76 | LRRK2 (0.67) | LRRK2MAOAMAOBPDGFRAFER | |
| SCHEMBL1368292 | 0.76 | LRRK2 (1.00) | LRRK2MAOAMAOBPDGFRAFER | |
| Isatin SCHEMBL34016 | 0.76 | MAOA (1.00) | LRRK2MAOAMAOBPDGFRAFER | |
| Isoindigo SCHEMBL29349649 | 0.76 | LRRK2 (0.67) | LRRK2MAOAMAOBPDGFRAFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2090571-B1 | Pyrimidine derivates, medicaments comprising them, their use and process of their preparation | BOEHRINGER INGELHEIM PHARMA (DE) | 2012-05-16 | — | — | EP | claimed |
| EP-2332924-A1 | Pyrimidine derivates, medicaments comprising them, their use and process of their preparation | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2011-06-15 | — | — | EP | claimed |
| JP-4460292-B2 | — | — | 2010-05-12 | — | — | JP | claimed |
| US-7709480-B2 | Pyrimidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-05-04 | — | — | US | claimed |
| EP-2090571-A1 | Pyrimidine derivates, medicaments comprising them, their use and process of their preparation | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2009-08-19 | — | — | EP | claimed |
| EP-1438053-B1 | PYRIMIDINE DERIVATIVES, PHARMACEUTICAL AGENT CONTAINING SAID COMPOUNDS, USE AND METHOD FOR MAKING SAME | BOEHRINGER INGELHEIM PHARMA (DE) | 2008-09-10 | — | — | EP | claimed |
| US-7173028-B2 | Pyrimidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-02-06 | — | — | US | claimed |
| US-20070015918-A1 | Derivatives of 1,3-diones having a herbicidal activity | ISAGRO RICERCA S.R.L (IT) | 2007-01-18 | — | — | US | claimed |
| CN-1882552-A | Derivatives of 1,3-diones having a herbicidal activity | ISAGRO RICERCA SRL (IT) | 2006-12-20 | — | — | CN | claimed |
| EP-1670772-A1 | DERIVATIVES OF 1,3-DIONES HAVING A HERBICIDAL ACTIVITY | Isagro Ricerca S.r.l. (IT) | 2006-06-21 | — | — | EP | claimed |
| US-20060100211-A1 | Pyrimidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-05-11 | — | — | US | claimed |
| JP-2005509624-A | — | — | 2005-04-14 | — | — | JP | claimed |
| WO-2005030736-A1 | DERIVATIVES OF 1,3-DIONES HAVING A HERBICIDAL ACTIVITY | ISAGRO RICERCA S.R.L. (IT) | 2005-04-07 | — | — | WO | claimed |
| EP-1438053-A1 | PYRIMIDINE DERIVATIVES, PHARMACEUTICAL AGENT CONTAINING SAID COMPOUNDS, USE AND METHOD FOR MAKING SAME | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-07-21 | — | — | EP | claimed |
| US-20030171359-A1 | Suitable for treatment of illnesses characterised by excessive or abnormal cell proliferation; viral, bacterial, fungal and/or parasitic infections, skin diseases, bone diseases, cardiovascular diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-09-11 | — | — | US | claimed |
| WO-2003032997-A1 | PYRIMIDINE DERIVATIVES, PHARMACEUTICAL AGENT CONTAINING SAID COMPOUNDS, USE AND METHOD FOR MAKING SAME | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-04-24 | — | — | WO | claimed |
| EP-2684874-B1 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and C-met inhibitors | CEPHALON INC (US) | 2017-05-17 | — | — | EP | disclosed |
| EP-2222647-B1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | CEPHALON INC (US) | 2015-08-05 | — | — | EP | disclosed |
| US-20030171359-A1 | Suitable for treatment of illnesses characterised by excessive or abnormal cell proliferation; viral, bacterial, fungal and/or parasitic infections, skin diseases, bone diseases, cardiovascular diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-09-11 | — | — | US | disclosed |
| WO-2003032997-A1 | PYRIMIDINE DERIVATIVES, PHARMACEUTICAL AGENT CONTAINING SAID COMPOUNDS, USE AND METHOD FOR MAKING SAME | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100211-A1 | Pyrimidine derivatives | TYMP, TYMS, DPYD | LRRK2 2772/4885MAOA 1800/4885MAOB 1408/4885 |
| US-20030171359-A1 | Suitable for treatment of illnesses characterised by excessive or abnormal cell proliferation; viral, bacterial, fungal and/or parasitic infections, skin diseases, bone diseases, cardiovascular diseases | COL1A1, MKI67, INSR | LRRK2 3765/4885MAOA 1170/4885MAOB 1029/4885 |
| US-20070015918-A1 | Derivatives of 1,3-diones having a herbicidal activity | DDT, CYP1B1, CYP51A1 | LRRK2 3682/4885MAOA 454/4885MAOB 547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.